HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jevnikar, A. M. Articles by Mannon, R. B. Search for Related Content PubMed PubMed Citation Articles by Jevnikar, A. M. Articles by Mannon, R. B.

Late Kidney Allograft Loss: What We Know about It, and What We Can Do about It

Anthony M. Jevnikar^*, and Roslyn B. Mannon

^* Departments of Medicine, Immunology, and Microbiology, Lawson Health Research Institute and Robarts Research Institute, London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada; and Transplantation Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

Correspondence: Dr. Roslyn B. Mannon, Transplantation Branch, NIDDK/NIH, 10 Center Drive, MSC 1450, CRC 5-5750, Bethesda, MD 20892. Phone: 301-594-7886; Fax: 301-451-6989; E-mail: rozm{at}mail.nih.gov

Despite dramatic improvements in immunosuppression, late graft loss after kidney transplantation remains a common and difficult problem. Histologic evaluation may reveal changes related to BK polyomavirus infection, hypertension, or calcineurin inhibitor toxicity, which can help to guide therapy. The designation chronic allograft nephropathy should thus be reserved for biopsies with tubular atrophy and interstitial fibrosis without an apparent cause. Although the cause clearly includes both antigen-dependent and antigen-independent events, the approach remains largely to exclude immune mechanisms. Although this review discusses the potential contribution of antibody to chronic injury, it focuses on the basic elements of kidney injury, the role of parenchymal cells in promoting injury, and the proliferative and inflammatory responses that accompanying injury. Strategies to manage these recipients include close attention to accompanying hypertension, diabetes, and hyperlipidemia, as well as consideration for altering immunosuppression; however, therapies that limit epithelial-to-mesenchymal transition or directly block fibrosis pathways may reduce chronic allograft fibrosis and may prove to be useful. Understanding the basic pathogenesis sufficiently to allow early intervention may finally benefit patients who are at high risk for tubular atrophy and interstitial fibrosis and promote their long-term graft function.

This article has been cited by other articles:

				N. Kieran, X. Wang, J. Perkins, C. Davis, E. Kendrick, R. Bakthavatsalam, N. Dunbar, P. Warner, K. Nelson, K. D. Smith, et al. Combination of Peritubular C4d and Transplant Glomerulopathy Predicts Late Renal Allograft Failure J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2260 - 2268. [Abstract] [Full Text] [PDF]